MESO

Mesoblast Limited is an Australian biotechnology company specializing in regenerative medicine and cell therapy. The company develops allogeneic cellular medicines using mesenchymal lineage precursor and stem cells for inflammatory diseases, cardiovascular conditions, and orthopedic disorders. Mesoblast has advanced multiple product candidates through clinical trials, with a focus on chronic heart failure, chronic low back pain, and acute graft versus host disease. The company has partnerships with major pharmaceutical companies for commercialization of its therapies.